Navigation Links
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Date:1/8/2008

SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- Corthera Inc. today announced the initiation of patient enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute care illnesses.

The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers worldwide. The primary outcome measure is the improvement of clinical signs and symptoms of acute heart failure, with additional secondary outcome measures, including improvement in renal function.

"With the current lack of safe and effective therapies for acute heart failure, we are very pleased to advance the development of Relaxin for the benefit of these patients," said Stan E. Abel, president and chief executive officer of Corthera. "The clinical and preclinical results to date are very encouraging, demonstrating Relaxin's beneficial hemodynamic properties."

According to the American Heart Association, heart failure is a costly cardiac and renal syndrome affecting more than 550,000 new patients per year, with projected direct and indirect costs at $33.2 billion in 2007. Acute heart failure is characterized by fluid overload (congestion), especially in the lungs, that causes shortness of breath and other complications. The current standard of care includes diuretics and vasodilators. Diuretics, which promote fluid excretion, are associated with renal complications. Vasodilators tested to date have been linked to hypotension, renal impairment and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and renal hemodynamic effects. Elevated levels of Relaxin are thought to modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured Relaxin has been shown to have these effects in multiple human studies of men and non- pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects can be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, Relaxin, is currently being evaluated in clinical trials for acute heart failure and preeclampsia. Corthera has worldwide rights to develop and commercialize Relaxin.

Contact: Timothy Engel or David Schull

Russo Partners

212.845.4242

timothy.engel@russopartnersllc.com

david.schull@russopartnersllc.com


'/>"/>
SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
7. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
8. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
9. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):